Dow Jones
39.387,76 +331,36 (+0,85%) Nasdaq
16.346,26 +43,46 (+0,27%) Nikkei 225
38.311,63 +237,65 (+0,62%) EUR/USD
1,0778 -0,0006 (-0,05%) Bitcoin EUR
58.388,68 +1.343,41 (+2,35%) CMC Crypto 200
1.350,74 +50,64 (+3,90%)
Rhythm Pharmaceuticals, Inc. (RYTM)
Dopo ore:
| Chiusura precedente | 38,92 |
| Aperto | 38,99 |
| Denaro | 38,44 x 100 |
| Lettera | 38,53 x 100 |
| Min-Max giorno | 37,96 - 39,30 |
| Intervallo di 52 settimane | 15,50 - 52,57 |
| Volume | |
| Media Volume | 593.866 |
| Capitalizzazione | 2,347B |
| Beta (5 anni mensile) | 1,93 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -4,63 |
| Prossima data utili | 30 lug 2024 - 05 ago 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 57,22 |
GlobeNewswireRhythm Pharmaceuticals Announces New Employment Inducement Grants
BOSTON, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced that on October 10, 2023, the Compensation Committee of Rhythm’s board of directors granted inducement equity grants covering an aggregate of 18,295 shares of its common stock to f
- GlobeNewswire
Rhythm Pharmaceuticals Announces Six Abstracts to be Presented at The Obesity Society’s Annual Meeting at ObesityWeek ®
BOSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced that six abstracts have been accepted for presentation – three oral presentations and three posters - at The Obesity Society’s Annual Meeting at ObesityWeek® to be held October 14-
- GlobeNewswire
Rhythm Pharmaceuticals Presents New Data at ESPE 2023
BOSTON, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced four oral presentations at the 61st Annual European Society for Paediatric Endocrinology (ESPE) Meeting being held September 21-23, 2023 in The Hague, Netherlands. “We are excited
